Pure Global
NCT02146222

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

Pharmacodynamic Study Using FLT-PET/CT in Patients With Advanced Solid Malignancies Treated With a Sequential Combination of X-82 and Docetaxel
University of Wisconsin, Madison·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
VEGFR/PDGFR dual kinase inhibitor X-82
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Wisconsin, Madison
Location
Madison, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2014
End date
Dec 01, 2016
Enrollment
14 participants
Primary outcome

Incidence of toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (Pharmacodynamic study),Changes in the FLT PET/CT vascular parameters for VEGF/PDGF dual kinase inhibitor X-82,Changes in the FLT PET/CT vascular parameters for the combination of VEGFR/PDGFR dual kinase inhibitor X-82 and docetaxel

Summary

This partially randomized phase I trial studies the side effects and how well sequential
 dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor
 receptor (PDGFR) dual kinase inhibitor X-82 and docetaxel works in treating patients with
 solid tumors. VEGFR/PDGFR dual kinase inhibitor X-82 may stop the growth of tumor cells by
 blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
 docetaxel, work in different ways to stop the growth of tumor cells, either by killing the
 cells, by stopping them from dividing, or by stopping them from spreading. Giving VEGFR/PDGFR
 dual kinase inhibitor X-82 and docetaxel one at a time instead of concurrently may work in
 treating patients with solid tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02146222
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02146222 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Wisconsin, Madison and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 14 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.